Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.
作者信息
Moseley Anna, Othus Megan, Garcia-Manero Guillermo, Appelbaum Frederick R, Erba Harry P, Walter Roland B
机构信息
Public Health Sciences Division and SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Leuk Lymphoma. 2021 Jul;62(7):1774-1777. doi: 10.1080/10428194.2021.1881512. Epub 2021 Feb 9.
Abstract
摘要
相似文献
1
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.预测成人急性髓系白血病强化诱导化疗的严重毒性：SWOG癌症研究网络试验S0106和S1203的分析
Leuk Lymphoma. 2021 Jul;62(7):1774-1777. doi: 10.1080/10428194.2021.1881512. Epub 2021 Feb 9.
2
Intensive induction in older patients with acute myeloid leukemia: an initial struggle with later rewards?老年急性髓系白血病患者的强化诱导治疗：初期艰难但后期有回报？
Haematologica. 2024 May 1;109(5):1331-1333. doi: 10.3324/haematol.2023.284780.
3
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms.急性髓系白血病和其他高级别髓系肿瘤成人患者强化诱导后与缓解后化疗的门诊护理比较。
Leuk Lymphoma. 2021 Jan;62(1):234-238. doi: 10.1080/10428194.2020.1821008. Epub 2020 Sep 13.
4
Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.≥70岁新诊断急性髓系白血病患者强化诱导化疗与基于去甲基化药物方案的对比
Hematol Oncol. 2018 Apr;36(2):495-497. doi: 10.1002/hon.2456. Epub 2017 Jun 30.
5
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.过去四十年中，“7+3”诱导化疗治疗急性髓系白血病的疗效改善：SWOG 试验数据分析。
Haematologica. 2023 Jan 1;108(1):42-47. doi: 10.3324/haematol.2022.280765.
6
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.柔红霉素60与柔红霉素90及伊达比星12用于急性髓系白血病诱导化疗的回顾性分析：梅奥诊所经验
Haematologica. 2022 Oct 1;107(10):2474-2479. doi: 10.3324/haematol.2022.281045.
7
Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia.探讨影响急性髓系白血病诱导治疗医院费用的决定因素。
Leuk Lymphoma. 2021 May;62(5):1211-1218. doi: 10.1080/10428194.2020.1855339. Epub 2020 Dec 10.
8
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.复发/难治性急性髓系白血病临床试验合格标准的经验性定义：对来自HOVON/SAKK和SWOG的1892例患者的分析
Haematologica. 2015 Oct;100(10):e409-11. doi: 10.3324/haematol.2015.130013. Epub 2015 Jul 9.
9
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.帕比司他联合强化诱导化疗治疗老年急性髓系白血病患者：I 期研究结果。
Clin Cancer Res. 2019 Aug 15;25(16):4917-4923. doi: 10.1158/1078-0432.CCR-19-0171. Epub 2019 May 31.
10
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?克拉屈滨在成人急性髓系白血病诱导缓解中的应用：我们处于什么位置？
Ann Hematol. 2019 Mar;98(3):561-579. doi: 10.1007/s00277-018-3562-8. Epub 2018 Nov 23.
引用本文的文献
1
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.接受强化化疗的急性髓系白血病患者因毒性而停药。
Blood Neoplasia. 2025 Jun 14;2(3):100129. doi: 10.1016/j.bneo.2025.100129. eCollection 2025 Aug.
2
Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.癌症治疗中的抗体药物偶联物：作用机制与临床研究
MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug.
本文引用的文献
1
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models.新诊断成人急性髓系白血病初始治疗的选择：预测模型的局限性。
Blood Rev. 2020 Nov;44:100679. doi: 10.1016/j.blre.2020.100679. Epub 2020 Mar 30.
2
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.快速供者识别可改善高危首次缓解的急性髓系白血病患者的生存。
JCO Oncol Pract. 2020 Jun;16(6):e464-e475. doi: 10.1200/JOP.19.00133. Epub 2020 Jan 27.
3
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness.老年急性髓系白血病患者的治疗选择：身体状况的问题。
Cancers (Basel). 2020 Jan 2;12(1):120. doi: 10.3390/cancers12010120.
4
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
5
Management of older or unfit patients with acute myeloid leukemia.老年或身体状况不佳的急性髓系白血病患者的管理。
Leukemia. 2015 Apr;29(4):770-5. doi: 10.1038/leu.2014.216. Epub 2014 Jul 9.
6
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.一项在急性髓细胞白血病年轻患者诱导和巩固治疗期间使用吉妥珠单抗奥佐米星的 3 期研究。
Blood. 2013 Jun 13;121(24):4854-60. doi: 10.1182/blood-2013-01-466706. Epub 2013 Apr 16.
7
The development and validation of two prediction models to identify employees at risk of high sickness absence.开发和验证两个预测模型，以识别高病假风险的员工。
Eur J Public Health. 2013 Feb;23(1):128-33. doi: 10.1093/eurpub/cks036. Epub 2012 Apr 25.
8
Quantitative analysis of the color change after iodine staining for diagnosing esophageal high-grade intraepithelial neoplasia and invasive cancer.碘染色后颜色变化的定量分析用于诊断食管高级别上皮内瘤变和浸润癌。
Gastrointest Endosc. 2009 Feb;69(2):213-8. doi: 10.1016/j.gie.2008.04.052. Epub 2008 Aug 20.
9
Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia?常规实验室检查能否区分严重急性呼吸综合征与社区获得性肺炎的其他病因？
Clin Infect Dis. 2005 Apr 15;40(8):1079-86. doi: 10.1086/428577. Epub 2005 Mar 16.
Zotero 插件